New drug IRL757 passes first safety check in healthy volunteers
NCT ID NCT06493045
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This early-stage study tested the safety of a new drug, IRL757, in 82 healthy adults aged 18-55. Participants received either the drug or a placebo to check for side effects and how the drug moves through the body. The study is complete and focused only on safety, not on treating any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOT DETERMINED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTC Clinical Trial Consultants AB, Uppsala University Hospital
Uppsala, Sweden
Conditions
Explore the condition pages connected to this study.